Novartis Bioventures Ltd, 10% Owner at Aeglea BioTherapeutics, Inc. (AGLE), sold 147,910 shares at $10.11 ($1.5M) on 2018-05-09, disclosed to the SEC on 2018-05-11.
Open-market sale of $1.5M AGLE by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.11 | 51,230 | $518K | 34.6% |
| 2 | $10.11 | 51,230 | $518K | 34.6% |
| 3 | $10.13 | 22,725 | $230K | 15.4% |
| 4 | $10.13 | 22,725 | $230K | 15.4% |
| Total | $10.12 avg | 147,910 | $1.5M | 100% |
| Filing → |
| GRTX | SELL | 2020-06-04 | $251K | — | Filing → |
| BCYC | BUY | 2019-05-30 | $2.4M | — | Filing → |
| ARPO | SELL | 2019-04-15 | $185K | — | Filing → |